Last reviewed · How we verify
NCT07231328: PIONEER
PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients)
trial testing There is no required Intervention for this Protocol. Based on Results for TruGraf/TRAC/TRAC ID Investigators may use the results in managing subjects Immunosuppression or rule out rejection. in Immunosuppression Management in 600 participants. Not yet recruiting.
31 December 2028
Quick facts
| Lead sponsor | Transplant Genomics, Inc. |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 20 November 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 March 2029 |
Drugs / interventions tested
- There is no required Intervention for this Protocol. Based on Results for TruGraf/TRAC/TRAC ID Investigators may use the results in managing subjects Immunosuppression or rule out rejection.
Conditions studied
- Immunosuppression Management — all drugs for Immunosuppression Management →
- Biomarkers / Blood — all drugs for Biomarkers / Blood →
- Subclinical Rejection — all drugs for Subclinical Rejection →
- Biopsy — all drugs for Biopsy →
Sponsor
Transplant Genomics, Inc. — full company profile →
Who can join
18 and older, any sex, with Immunosuppression Management or Biomarkers / Blood. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational, prospective, multi-center trial designed to evaluate clinical outcomes in kidney transplant recipients undergoing TruGraf and TRAC monitoring. Approximately 15 U.S. sites
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07231328
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Transplant Genomics, Inc. trials
Trials by the same sponsor.
- NCT07393594 — ID-ENTITY Trial- Evaluating Serial T-ID Monitoring · not yet recruiting
- NCT05335538 — TruGraf and TRAC In Pediatrics Study · unknown
- NCT04670926 — Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test · NA · unknown
- NCT04267016 — Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care · terminated
- NCT04398498 — Molecular Biomarkers in Renal Transplantation Via TruGraf® Test · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07231328 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Transplant Genomics, Inc.
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07231328.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing